Agenus vs Atara Biotherapeutics
Atara Biotherapeutics reported revenue of $121 million in fiscal 2025, about the same as Agenus' $114 million in fiscal 2025. Agenus' revenue grew 10.4% in its latest year, and Atara Biotherapeutics' fell 6.3%. Agenus had an operating margin of -17.7%, against 29.7% at Atara Biotherapeutics. Free cash flow was −$77 million at Agenus and −$51 million at Atara Biotherapeutics.
Side by side
| Agenus | Atara Biotherapeutics | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $114M | $121M |
| Revenue growth | 10.4% | −6.3% |
| Revenue growth a year, last 5 years | 5.3% | — |
| Gross margin | 99.1% | — |
| Operating margin | −17.7% | 29.7% |
| Net margin | −2.7% | 27.1% |
| Free cash flow | −$77M | −$51M |
| Free cash flow margin | −67.6% | −42.2% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 38.5% | 69.8% |
| Last close | $6.14 | $6.34 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | — | bought $5.7 million, sold $3.8 million |
| Piotroski F-score | 3 of 9 | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
AgenusAtara Biotherapeutics
Operating margin
Percent of revenue
AgenusAtara Biotherapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
AgenusAtara Biotherapeutics
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Agenus and Atara Biotherapeutics pages.